Alyeska Investment Group
CCCC icon

Alyeska Investment Group’s C4 Therapeutics CCCC Stock Holding History

Alyeska Investment Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-131,250
Closed -$3.18M – 575
2022
Q1 		$3.18M Buy
131,250
+6,250
+5% +$152K 0.04% 354
2021
Q4 		$4.03M Hold
125,000
– – 0.05% 315
2021
Q3 		$5.58M Buy
+125,000
New +$5.35M 0.07% 304

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Alyeska Investment Group's CCCC Position: Q2 2022 in Review

Alyeska Investment Group sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 131,250 shares — an estimated $3.18M sold.

Alyeska Investment Group first reported a position in CCCC in Q3 2021 and held it in 3 quarters. The position peaked at $5.58M in Q3 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • Alyeska Investment Group reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 131,250 C4 Therapeutics shares in Q2 2022, an estimated $3.18M.
  • Alyeska Investment Group first reported a position in C4 Therapeutics in Q3 2021 and held it in 3 quarters.
  • Alyeska Investment Group's C4 Therapeutics position peaked at $5.58M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on Alyeska Investment Group's 13F filing for Q2 2022, filed 15 Aug 2022.